Sei Investments Co. grew its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 68.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 391,170 shares of the biopharmaceutical company’s stock after buying an additional 159,002 shares during the quarter. Sei Investments Co. owned 0.24% of Horizon Pharma worth $4,961,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in shares of Horizon Pharma by 82.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 69,626 shares during the period. Neuberger Berman Group LLC acquired a new stake in shares of Horizon Pharma during the 2nd quarter worth about $7,147,000. Ameriprise Financial Inc. acquired a new stake in shares of Horizon Pharma during the 2nd quarter worth about $4,865,000. Bank of New York Mellon Corp raised its position in shares of Horizon Pharma by 19.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 915,421 shares of the biopharmaceutical company’s stock worth $10,866,000 after acquiring an additional 150,850 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Horizon Pharma by 348.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 101,900 shares of the biopharmaceutical company’s stock worth $1,292,000 after acquiring an additional 79,200 shares in the last quarter. Institutional investors and hedge funds own 86.59% of the company’s stock.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at $14.44 on Wednesday. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $2,304.23, a price-to-earnings ratio of 10.19, a price-to-earnings-growth ratio of 1.19 and a beta of 1.31. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $20.25.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The business had revenue of $271.60 million for the quarter, compared to the consensus estimate of $259.74 million. During the same period in the prior year, the business earned $0.70 earnings per share. The business’s revenue was up 30.1% on a year-over-year basis. equities analysts predict that Horizon Pharma PLC will post 0.72 EPS for the current year.
Several equities research analysts have recently weighed in on HZNP shares. Piper Jaffray Companies set a $18.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, September 10th. Mizuho reaffirmed a “hold” rating and set a $12.00 price target (up previously from $9.00) on shares of Horizon Pharma in a research report on Monday, August 28th. Zacks Investment Research lowered Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. ValuEngine lowered Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Jefferies Group lifted their price target on Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $18.75.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.